Relin Medicine was founded in 1996. Adhering to the belief of “pooling global resources to serve Chinese healthcare industry”, featured as a general agent and its academic promotion, with advantages in ophthalmology, Relin Medicine has gradually developed into a pharmaceutical enterprise that integrates new drug introduction and R&D, marketing authorization holding, and specialized promotion.

The company's marketing model is mainly self-operated with recruiting agencies as supplement. It has established 34 branches which is a specialized sales network covering the entire country. As a leader in the ophthalmological prescription drug market, the company has carefully introduced high-quality products around the world and, through specialized academic promotion, has created 12 leading prescription drugs that have taken the top market share in their respective categories. With the booming development of the healthcare industry and the unique advantages of its main products, Relin has also established its own retail business division. With its accumulated prescription user base, excellent quality approved by generations and the company’s modern media approach, HYLO COMOD®(sodium hyaluronate eye drops) has risen as a star in the entire OTC field. The company has become a leader in raising public awareness of eye health.

Since 2005, Relin Medicine has been committed to independent research and development with the goal of meeting clinical needs. As the world's first innovator to apply Levofloxacin to the field of otology, Relin obtained a new drug certificate and production license for this product, named Zuofu® in 2009. This product has consistently taken the top market share due to its superior antibacterial effect. Through an open and diverse international cooperation model, Relin has introduced or invested in high-quality and potential products worldwide. Among them, the first-in-class drug MS-553 has been selected as the 12th Five-Year Plan of the National Major Scientific and Technological Special Project for “Significant New Drugs Innovation and Development”. International multi-center clinical trials are being conducted at several globally renowned centers led by Ohio State University (OSU), and significant clinical efficacy has been demonstrated in Phase I/II clinical trials for several indications, including cancer, ocular fundi disease, and autoimmune diseases. MS-553 has the potential to become a top 10 product in the world.